Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Adjuvant selpercatinib reduces recurrence in RET-positive lung cancer

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

The potential of T-cell engagers in SCLC treatment

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC